Mesothelioma Researcher Receives Pioneer Award

Dr. Michele Carbone

Dr. Michele Carbone spoke at the Meso Foundation’s 2013 International Symposium on Malignant Mesothelioma

The Mesothelioma Applied Research Foundation announced today that the 2014 recipient of its Pioneer Award is Michele Carbone, MD, PhD, for his remarkable achievements in mesothelioma research.

Michele Carbone, MD, PhD is a Professor of Pathology and the Director of the University of Hawaii Cancer Center, a National Cancer Institute designated Consortium Cancer Center affiliated with the University of Hawaii – Manoa. He has published over 150 peer-reviewed papers, most in the area of the pathogenesis of mesothelioma.

In addition to his impressive publication record, Dr. Carbone is known in the mesothelioma community for his tireless work in the Turkish region of Cappadocia, where mesothelioma causes 50% of all deaths. Dr. Carbone discovered that a combination of environmental exposures and genetic predisposition were the reason for such a high incidence of mesothelioma among the villagers. Taking his role as a scientist a step further, alongside famed Turkish professor Izzettin Baris, Dr. Carbone demonstrated his compassion by convincing the Turkish government to move and rebuild the affected villages, thus removing them from the environmental exposures.

Dr. Carbone’s studies in Turkey led him to a life-long quest to identify genes implicated in mesothelioma. In 2001, he published in “The Lancet” that predisposition to developing mesothelioma was transmitted as an in an autosomal dominant character in certain Turkish families.

Subsequently, back in the United States, Dr. Carbone and Joseph Testa, PhD led their research team, which included Drs. Giovanni Gaudino, Harvey Pass, Jianming Pei, Mitchell Cheung, and Haining Yang, to study US families with a high incidence of mesothelioma, and through this collaboration discovered the “BAP1 cancer syndrome.” They found this “syndrome” to be caused by germline mutations of the BAP1 gene, which is characterized clinically by a very high risk of developing mesothelioma, melanoma, and other cancers.

Dr. Carbone is known in his field as a generous mentor, and has helped several prolific scientists enter the field of mesothelioma research. Dr. Haining Yang, is one researcher whose work with Dr. Carbone resulted in a peer-reviewed grant award of $100,000 from the Mesothelioma Applied Research Foundation which helped her to develop the data that allowed her two years later to win her NCI-RO1 and DOD grants to study mesothelioma.

“I have worked closely with Dr. Carbone over the years and have been impressed by his kindness and availability,” said Mary Hesdorffer, NP, Meso Foundation’s executive director. “He has been a leader in the field of mesothelioma research, and every one of his many contributions brings us that many steps closer to life-saving treatments for mesothelioma patients.”

The Pioneer Award honors individuals “pioneering” scientific advances in the field of mesothelioma, with the goal of eradicating the life-ending and vicious effects of mesothelioma. The award will be presented during the Awards Dinner, at the International Symposium on Malignant Mesothelioma in Alexandria, VA, on March 5-7.

Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. Medical experts consider it one of the most aggressive and deadly of all cancers. Approximately 3,500 Americans are diagnosed with mesothelioma every year and an estimated one-third were exposed while serving in the Navy or working in Navy shipyards.

ABOUT THE MESOTHELIOMA APPLIED RESEARCH FOUNDATION
The Meso Foundation is the only 501(c)3 non-profit organization dedicated to eradicating mesothelioma and easing the suffering caused by it. The Meso Foundation actively seeks philanthropic support to fund peer-reviewed mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer reviewed scientific research to establish more effective treatments for mesothelioma and, ultimately, a cure for this extremely aggressive cancer. To date, the Foundation has awarded over $8.7 million to research.

More information is available at http://www.curemeso.org.

FROM THE HEADLINES: International Team from the University of Hawai’i Identifies Protein Critical in Development of Mesothelioma

Former Mesothelioma Applied Research Foundation’s grant recipient, Dr. Haining Yang  (University of Hawai’i), is once again making news with the recent discovery of a protein that is activated following exposure to asbestos leading to the development of malignant mesothelioma.  As reported by MedicalXpress.com, Dr. Haining Yang, PhD, and an international team of researchers have identified HMGB1 as a critical protein in the development of malignant mesothelioma. Dr. Yang’s findings are the cover story of the July 1’s Cancer Research, one of the nation’s leading cancer research publications.

“We are very excited about this discovery and are extremely pleased that it was also chosen to be the featured cover story,” said Yang. “The next step is to translate this discovery into actual treatments for mesothelioma patients.”

This discovery into the growth of mesothelioma offers scientists an opportunity to develop specific therapies for mesothelioma patients. Mesothelioma, a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos is considered one of the most aggressive of all cancers. Approximately 3,000 Americans are diagnosed with mesothelioma every year, yet available treatments have limited effectiveness. Identifying this biomarker for early detection will help shed light on developing new treatments for mesothelioma prevention and therapy.

Earlier this year this same lab worked collaboratively with others to announce the first gene associated with malignant mesothelioma BAP1. Dr. Giovanni Gaudino from the University of Hawai’i will be discussing BAP1 and its possible utility as a target for therapy and identifying those at high risk to develop mesothelioma at the Meso Foundation’s 2012 Symposium during the “Demystifying Scientific Breakthroughs” panel. It is a very exciting time for mesothelioma research and the promise for further scientific breakthroughs will be the focus of discussion at the Symposium.

The current study was an international effort and included investigators from the University of Hawai‘i Cancer Center, the John A Burns School of Medicine in Honolulu, the San Raffaele University and Research Institute in Milan, Italy, the National Institutes of Health in Bethesda, Md., and the New York University School of Medicine.